Source-grounded facts extracted from Vaxart, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vaxart, Inc. reported the first quarter of 2026 results: revenue $39.2 million, net income $5.2 million, EPS $0.02.
“funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the first quarter of 2026 was $39.2 million, compared to $20.9 million for the first quarter of 2025. Revenue in the first quarter of 2026 and the first quarter of 2025 was primarily from government contracts related to”
Vaxart, Inc. issued 447,067 shares of Common Stock (the "Commitment Shares") of common stock to Lincoln Park Capital Fund, LLC for Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock.
“rights agreement (the “ Registration Rights Agreement ”), with Lincoln Park Capital Fund, LLC (“ Lincoln Park ”), pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), subject to certain limitations and satisfaction of the conditions set forth in the Purchase”
Vaxart, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25.0 million (effective 2026-04-16).
“On April 16, 2026, Vaxart, Inc. (the “Company”) entered into a purchase agreement (the “ Purchase Agreement ”) and a registration rights agreement (the “ Registration Rights Agreement ”), with Lincoln Park Capital Fund, LLC (“ Lincoln Park ”), pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company’s common stock”
Vaxart, Inc. reported the full year ended December 31, 2025 results: revenue $237.3 million, net income $16.3 million, EPS $0.07.
“non-dilutive funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the full year 2025 was $237.3 million, compared to $28.7 million for the full year 2024. Revenue in the full year 2025 and the full year 2024 was primarily from government contracts related to the BARDA contract”
Vaxart, Inc. terminated Lease Agreement with Britannia Pointe Grand Limited Partnership valued at Termination of Lease Agreement effective May 15, 2026 (effective 2025-12-18).
“On December 18, 2025, Vaxart, Inc., a Delaware corporation (the “Company”), entered into a termination agreement (the “Termination Agreement”) with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership (the “Landlord”), in connection with the termination of that certain lease agreement, by and between the Landlord and the Company, dated September 17, 2021 (the “Lease”) for certain premises located at 170 Harbor Way, South San Francisco, California 94080 that served as the Company’s headquarters.”
Vaxart, Inc. received a nasdaq delisting notice notice regarding other.
“September 19, 2025, the Company received a letter from the Office of the General Counsel of Nasdaq, stating that the Company’s securities will be delisted from Nasdaq as a result of the Company’s noncompliance with the Panel’s Conditions. Trading in the Company’s common stock on Nasdaq was suspended at the open of trading on July 8, 2025. The Company’s common stock is currently quoted on the OTCQX® Best Market under the symbol “VXRT.” SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unde”
Vaxart, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).
“to timely request a hearing by July 8, 2025, then the Hearings Department will take action to follow procedures to delist the Company’s common stock. The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series and is considering all options with regard to its stock listing, including efforts to regain compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will stay delisting but will not stay the tra”
Jeroen Grasman was appointed as Chief Financial Officer at Vaxart, Inc..
“On May 13, 2025, the Company announced that its Board of Directors had appointed Jeroen Grasman to serve as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective as of May 19, 2025.”
Phillip Lee resigned as Chief Financial Officer at Vaxart, Inc..
“On May 12, 2025, Phillip Lee notified the Company of his intention to resign as the Chief Financial Officer of Vaxart, Inc. (the “Company”) and as the Company’s Principal Accounting Officer and Principal Financial Officer, effective upon the appointment of a new Chief Financial Officer.”
Robert A. Yedid resigned as Director at Vaxart, Inc..
“Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025”
Kevin Finney was appointed as Director at Vaxart, Inc..
“the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025”
Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until December 30, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until June 30, 2025”
Steven Lo was appointed as Chief Executive Officer, President, and director at Vaxart, Inc..
“On March 4, 2024, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) appointed Steven Lo as the Company’s Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the “Start Date”).”
Michael J. Finney changed role as Interim President and Chief Executive Officer at Vaxart, Inc..
“In connection with Mr. Lo’s appointment, Michael J. Finney, Ph.D. will step down as the Company’s Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board.”
Andrei Floroiu resigned as Chief Executive Officer at Vaxart, Inc..
“On January 31, 2024, the Company entered into a Separation Agreement with Mr. Floroiu (the “Separation Agreement”).”
Vaxart, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until January 17, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until July 15, 2024”
Vaxart, Inc. entered into ASPR Contract with U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR") valued at $9,271,193.00 (effective 2024-01-12).
“On January 12, 2024, Vaxart, Inc. (the “Company”) was awarded a contract (the “ASPR Contract”) by the U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the “ASPR”). Under the ASPR Contract, the Company will receive an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company’s XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events.”
Vaxart, Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P valued at approximately $10 million (effective 2024-01-16).
“On January 16, 2024, Vaxart, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with RA Capital Healthcare Fund, L.P (“RA Capital”).”
David Wheadon was appointed as Lead Director at Vaxart, Inc..
“On January 15, 2024 David Wheadon, M.D. was appointed to serve as Lead Director of the Board and will receive an annual cash retainer equal to $25,000 for such service”
Michael J. Finney was appointed as Interim Chief Executive Officer at Vaxart, Inc..
“On January 16, 2024, the Board announced that, effective as of January 16, 2024, the current Chair of the Board, Michael J. Finney, Ph.D, has been appointed as Interim Chief Executive Officer of the Company.”
Andrei Floroiu resigned as President, Chief Executive Officer and Member of the Board of Directors at Vaxart, Inc..
“On January 15, 2024 (the “Separation Date”), Andrei Floroiu resigned (i) as President and Chief Executive Officer of the Company, and (ii) as a member of the Company’s Board of Directors”
Vaxart, Inc.: Amended and restated bylaws to conform to recent DGCL amendments, reduce stockholder meeting quorum from majority to at least one-third, update advance notice provisions for nominations and other business, and make other clarifying and procedural changes (effective 2023-10-18).
“On October 18, 2023, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”) approved and adopted the Amended and Restated Bylaws of the Company (the “Bylaws”), effective [immediately], to update the bylaws to conform certain provisions to the Delaware General Corporation Law (the “DGCL”) in light of, among other things, recent amendments to the DGCL, to make clarifying changes, and to effect certain other changes regarding internal procedural matters, including the following changes”
Vaxart, Inc. reported the quarter ended June 30, 2023 results: revenue $1.4 million, net income $22.6 million, EPS $0.16.
“loss per share for the second quarter of 2023 was $0.16, compared to a net loss of $0.23 per share in the second quarter of 2022. ● Revenue for the second quarter of 2023 was $1.4 million, compared to no revenue in the second quarter of 2022. Revenue in the second quarter of 2023 was primarily from revenue recognized for work performed under Vaxart’s grant from”
Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“July 21, 2023, Vaxart, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per sh”
Vaxart, Inc. shareholders approved Non-binding advisory vote on the frequency of the advisory vote on executive compensation at the 2023-06-26 meeting.
“Proposal 4 . Stockholders voted on a non-binding advisory basis on the frequency of the advisory vote on the compensation of the Company’s named executive officer (the “Say-on-Frequency Proposal”). The voting results were as follows: Once Every Year Every Two Years Every Three Years Abstain 25,454,444 1,853,035 1,867,998 2,679,132”
Vaxart, Inc. shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement at the 2023-06-26 meeting.
“Proposal 3 . Stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 18,890,423 11,637,307 1,326,879 42,397,502”
Vaxart, Inc. shareholders approved Ratification of the selection of WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-26 meeting.
“Proposal 2 . Stockholders ratified the selection of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 67,434,986 3,868,365 2,948,760 -”
Vaxart, Inc. shareholders approved Election of six nominees for directors to serve until the 2024 annual meeting at the 2023-06-26 meeting.
“Proposal 1 . Stockholders elected the six nominees for directors to serve until the Company’s 2024 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Michael J. Finney, Ph.D. 27,992,065 3,862,544 42,397,502 Andrei Floroiu 23,771,964 8,082,645 42,397,502 Elaine J. Heron, Ph.D. 28,489,847 3,364,762 42,397,502 W. Mark Watson 27,950,477 3,904,132 42,397,502 David Wheadon, M.D. 27,167,509 4,687,100 42,397,502 Robert A. Yedid 23,166,022 8,688,587 42,397,502”
Vaxart, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. (effective 2023-06-07).
“On June 7, 2023, Vaxart, Inc. (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to issue and sell to Cantor 16,000,000 shares of the Company’s common stock, par value $0.0001 (the “Common Shares”) in an underwritten public offering (the “Offering”), pursuant to a Registration Statement on Form S-3 (File No. 333-270671) and the related prospectus and prospectus supplement, in each case filed with the U.S. Securities and Exchange Commission (the “SEC”).”
Fuad Ahmad departed as Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer at Vaxart, Inc..
“As of December 15, 2022, Fuad Ahmad ceased to serve as the Company’s Interim Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer.”
Phillip E. Lee was appointed as Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer at Vaxart, Inc..
“On December 15, 2022 (the “ Start Date ”), Vaxart, Inc. (the “ Company ”) appointed Phillip E. Lee as the Company’s Chief Financial Officer and as the Company’s Principal Accounting Officer and Principal Financial Officer.”
Vaxart, Inc. reported financial results for the quarter ended September 30, 2022.
“On November 8, 2022, Vaxart, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Elaine J. Heron was appointed as Director at Vaxart, Inc..
“on August 25, 2022, the Board appointed Elaine J. Heron, Ph.D., to serve on the Board to fill the vacancy caused by Dr. Cherrington’s resignation”
Julie Cherrington resigned as Director at Vaxart, Inc..
“On August 23, 2022, Julie Cherrington, Ph.D. resigned from the Board of Directors (the “ Board ”) of Vaxart, Inc.”
Margaret Echerd retired as Principal Accounting Officer at Vaxart, Inc..
“and Margaret Echerd ceased to serve as the Company’s Principal Accounting Officer.”
Andrei Floroiu departed as Principal Financial Officer at Vaxart, Inc..
“As of May 10, 2022, Andrei Floroiu ceased to serve as the Company’s Principal Financial Officer”
Fuad Ahmad was appointed as Interim Chief Financial Officer at Vaxart, Inc..
“On May 10, 2022, Vaxart, Inc. (the “ Company ”) retained Fuad Ahmad, a partner at FLG Partners, LLC (“ FLG Partners ”), a chief financial officer services and board advisory consulting firm, as the Company’s Interim Chief Financial Officer and, in his capacity as a non-employee consultant, as the Company’s Principal Financial Officer and Principal Accounting Officer while Vaxart conducts its ongoing search for a Chief Financial Officer.”
Margaret Echerd departed as Senior Vice President and Principal Accounting Officer at Vaxart, Inc..
“On March 28, 2022, Margaret Echerd notified Vaxart, Inc. (the “ Company ”) that she intends to retire as Senior Vice President and Principal Accounting Officer, effective as of May 5, 2022.”
Julie M. Cherrington was appointed as Director at Vaxart, Inc..
“On August 20, 2021, the Board of Directors (the “ Board ”) of Vaxart, Inc. (the “ Company ”) appointed Julie M. Cherrington, Ph.D., to serve on our Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.